CELL AND GENE THERAPY
Ocean Genomics, Geninus Inc | March 30, 2021
Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers.
The two organizations will dispatch in Korea Ocean Genomics' high level AI-based transcriptome analysis and biomarker stage (txome.ai) as both a cloud-put together and with respect to premises arrangement. Geninus will use the txome.ai stage to extend its CancerSCAN clinical diagnostics stage for its clinic clients, and for biomarker revelation administrations with scholastic and biotechnology customers. Ocean Genomics and Geninus will likewise accomplice on the co-development of a progression of RNA-educated multidimensional biomarkers for research and clinical use.
“We are excited to embark on this partnership with Geninus” said Carl Kingsford, co-founder and CEO, Ocean Genomics. “Ocean Genomics’ expertise in AI and computational method development, together with Geninus’ translational experts and access to data is a powerful combination. Working together, we can advance the field and enhance the uses of RNA biomarkers in clinical and research applications – and provide essential insights for clinicians who care for cancer patients.”
Dr. Woong Yang Park, CEO, Geninus, said, “Genome analysis for precision cancer medicine is becoming an essential process in hospitals. Gene expression analysis on tumor tissue RNA can deliver critical information for targeted therapy and immunotherapy. We expect to advance precision medicine by incorporating Ocean Genomics’ txome.ai into Geninus’ clinical diagnostics platform, CancerSCAN. We look forward to working with Ocean Genomics in co-developing biomarkers and expanding services to our academic and biotechnology customers.”
About Ocean Genomics, Inc.
Ocean Genomics’ mission is to enable drug development and personalized medicine by combining AI with advanced gene-expression analysis to determine rich gene expression signatures and develop RNA-informed multidimensional biomarkers. DNA is a predictor of what might happen in the future, while RNA reveals what’s happening now, making it an essential component in drug development, screening and monitoring, diagnosis and treatment selection. Analyzing RNA requires far more advanced software and computational methods than analyzing DNA.
Ocean Genomics provides the required specialized expertise in AI and transcriptomic analysis and advanced computational software solutions required to power discovery and development programs with life sciences companies and academic researchers. Ocean Genomics provides a self-service, fully configured, cloud-based platform, txome.ai, which provides advanced transcriptome analysis and biomarker generation.
About Geninus Inc.
Geninus provides clinical genome analysis solutions for precision medicine clinics. CancerSCAN, a cancer genome diagnostics platform, is used to inform personalized cancer treatment with targeted therapeutics and immunotherapy in major hospitals in Korea and Japan. CancerSCAN includes an information management system, a bioinformatics pipeline, variant annotation, clinical reports, and datacenter. OncoSTATION, a user interface for CancerSCAN, can be installed within hospital information systems. In addition, Geninus operates a single cell genome analysis platform called Celinus for biomarker discovery. Through collaborations with clinicians and pharmaceutical companies, Celinus can unearth new druggable targets or diagnostic markers in tumor microenvironment cells.
CELL AND GENE THERAPY
I-Mab | July 12, 2021
I-Mab, a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercialization of novel biologics, announced today the signing of two new partnerships with Chinese emerging biotech firms to enhance its next-generation innovation pipeline.
Collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company, provide I-Mab access to revolutionary technologies to search for new cancer treatments. I-Mab will create new anti-cancer antibody therapies using Immorna's ground-breaking self-replicating mRNA technology. Furthermore, I-Mab will collaborate with neoX Biotech on up to ten new biologics programs that will use neoX's unique artificial intelligence algorithm under a strategic partnership agreement. Today's announcement adds to the Company's existing collaboration agreements with Complix for a cell-penetrating antibody platform and Affinity for a masking antibody platform in March 2021, allowing it to continue expanding its globally competitive pipeline of next-generation antibody assets enabled by transformative technologies.
The cooperation agreements specify that both partner firms will earn secret upfront and milestone payments.
I-Mab is a global biotech business focused on discovering, developing and ultimate commercialization of new and highly distinct biologics in the immuno-oncology therapeutic space. Through drug discovery, the Company's goal is to deliver transformational medicines to patients all around the globe. I-internationally, Mab's competitive pipeline of more than 15 clinical and preclinical stage therapeutic candidates is driven by its internal R&D capabilities and global licensing agreements based on the Company's exclusive Fast-to-Proof-of-Concept and Fast-to-Market pipeline development methods. The Company is quickly transitioning from clinical-stage biotech to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility, and commercialization capacity. I-Mab has a global presence in Shanghai, Beijing, Hangzhou, Hong Kong in China, and Maryland and San Diego in the United States.
Immorna, founded in 2019, is a rapidly expanding biotech company focused on creating self-replicating and traditional mRNA-based therapeutics and vaccines. Immorna has developed a strong CMC platform for mRNA synthesis, purification, and analytical testing since its inception, and it is ideally suited for commercial development. In addition, Immorna has developed an arsenal of mRNA delivery vehicles using cutting-edge screening tools, including polymers and lipid nanoparticles containing multiple proprietary cationic lipids suited for intramuscular, intravenous, or tissue-targeting delivery. Immorna's pipeline is diverse, including cancer immunotherapy, infectious diseases, rare genetic disorders, and cosmetology. Immorna's oncology and infectious disease projects are nearing the clinical stage. Immorna's global presence includes Hangzhou, Shanghai in China, and Wilmington, DE in the United States.
About neoX Biotech
neoX Biotech is a next-generation biotech firm that focuses on computational design for novel drug research and development. neoX focuses on studying and developing macromolecular medicines and multi-specific drugs by combining artificial intelligence (AI), biophysics, and high-throughput experiments. neoX has created a highly transferable and sophisticated platform for early drug discovery via in-depth protein-protein interaction analysis (PPI). NeoX has shown preclinical success in a number of novel drug pipelines derived from this platform. Founded in 2018 by two physicians from MIT and Caltech, neoX has received over $100 million in funding from renowned venture capital firms such as Sequoia Capital China, 5Y Capital, Vision Plus Capital, Vertex Ventures, LYFE Capital, ZhenFund, and others.
Ebanga | December 29, 2020
Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients.
Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.
Wendy Holman, CEO and co-founder of Ridgeback, said: “I speak on behalf of the entire Ridgeback Bio team when I say thank you to all of the dedicated and thoughtful groups who helped contribute to this historic and important product approval. Ridgeback is grateful to NIAID’s Vaccine Research Center (VRC) and the Democratic Republic of the Congo’s (DRC) Institut National pour la Recherche Biomédicale (INRB). Specifically, the brilliance of three individuals needs to be acknowledged -- Dr. Nancy Sullivan (VRC), Dr. John Mascola (VRC) and Professor Jean-Jacques Muyembe-Tamfum (INRB). It was their mission to create a lyophilized single-use Ebola treatment, and in partnership with the team at Ridgeback, that vision became a reality. We would also like to thank FDA leadership and the Ebanga review team at FDA’s Division of Antivirals (DAV) for their focused and thorough review of this product. Finally, the true heroes are the patients and their families who allowed themselves to be carried away from their homes – not knowing if they would ever return – in order to enroll in a randomized controlled trial at the Ebola treatment centers during the 2018-2020 Ebola outbreak in the DRC. Your trust and belief in science, innovation and the people caring for you has transformed Ebola forever. Thanks to you, Ebola is now a treatable disease.”